Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24450767 | 0.79 | L3MBTL1 (0.37) | L3MBTL1DGAT1 | |
| SCHEMBL10924783 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL27762430 | 0.71 | CA12 (0.31) | — | |
| SCHEMBL7337965 | 0.71 | — | — | |
| SCHEMBL725542 | 0.70 | — | — | |
| SCHEMBL4928898 | 0.70 | — | — | |
| SCHEMBL151549 | 0.70 | — | — | |
| SCHEMBL1756947 | 0.69 | — | — | |
| SCHEMBL4689982 | 0.69 | — | — | |
| SCHEMBL7327163 | 0.69 | EGFR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8512971-B2 | Compounds and methods of use thereof for assaying lysophospholipase D activity | ECHELON BIOSCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-7989663-B2 | Compounds and methods of use thereof for assaying lysophospholipase D activity | ECHELON BIOSCIENCES INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100260682-A1 | Compounds and methods of use thereof for assaying lysophospholipase D activity | ECHELON BIOSCIENCES INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
| US-20090068697-A1 | Compounds and methods of use thereof for assaying lysophospholipase D activity | ECHELON BIOSCIENCES INCORPORATED (US) | 2009-03-12 | — | — | US | disclosed |
| US-7459285-B2 | Compounds and methods of use thereof for assaying lysophospholipase D activity | ECHELON BIOSCIENCES INCORPORATED (US) | 2008-12-02 | — | — | US | disclosed |
| US-20040171096-A1 | Compounds and methods of use thereof for assaying lysophospholipase D activity | ECHELON BIOSCIENCES INCORPORATED | 2004-09-02 | — | — | US | disclosed |
| WO-2004053459-A2 | COMPOUNDS AND MEHTODS OF USE THEREOF FOR ASSAYING LYSOPHOSPHOLIPASE D ACTIVITY | ECHELON BIOSCIENCES INCORPORATED (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-1034164-B1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068697-A1 | Compounds and methods of use thereof for assaying lysophospholipase D activity | LYPLAL1, LPCAT3, LPCAT1 | L3MBTL1 417/4885ALDH1A1 2846/4885TP53 3578/4885 |
| US-20100260682-A1 | Compounds and methods of use thereof for assaying lysophospholipase D activity | LYPLAL1, LPCAT3, LPCAT1 | L3MBTL1 417/4885ALDH1A1 2846/4885TP53 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.